CRANSTON, R.I. , Nov.
20, 2024 /PRNewswire/ -- In National Diabetes Awareness Month, Abacus Health Solutions announces the results of a cost savings analysis of their patented Diabetes Care Rewards Program. Over the last 17 years, Abacus has continued to innovate and provide its Diabetes Program to individuals through their employers. The Program incentivizes long-term health behaviors and has proven to dramatically reduce costs of diabetes care for both employers and individuals with all types of diabetes.
Demand for GLP medications has grown as diabetes is the fastest-growing chronic disease globally. Newer GLP medications, Ozempic and Mounjaro, have a lot of research support for the clinical value for diabetes members, including blood glucose control, weight loss, and reduced cardiovascular events. While GLP medications are an effective treatment for Type 2 diabetes, the cost can be a barrier to many people and their employers.
With an average cost of over $1,000 per monthly fill, many employers are struggling with skyrocketing use. An analysis was conducted using medical and pharmacy claims data for a large municipal client who has been using the Abacus Program for three years. The client has over 70,000 total lives on their collective health plans and over 4,000 members with diabetes.
The results in the chart below show how these expensive medications can add value by having a significant impact on reducing costly hospital admissions in a diabetic population. Diabetes is.